CAR-T cell therapy: a potential new strategy against prostate cancer

J Immunother Cancer. 2019 Oct 16;7(1):258. doi: 10.1186/s40425-019-0741-7.

Abstract

Prostate cancer (PCa) is one of the main causes of cancer-related death in men. In the present immunotherapy era, several immunotherapeutic agents have been evaluated in PCa with poor results, possibly due to its low mutational burden. The recent development of chimeric antigen receptor (CAR)-T cell therapy redirected against cancer-specific antigens would seem to provide the means for bypassing immune tolerance mechanisms. CAR-T cell therapy has proven effective in eradicating hematologic malignancies and the challenge now is to obtain the same degree of in solid tumors, including PCa. In this study we review the principles that have guided the engineering of CAR-T cells and the specific prostatic antigens identified as possible targets for immunological and non-immunological therapies. We also provide a state-of-the-art overview of CAR-T cell therapy in PCa, defining the key obstacles to its development and underlining the mechanisms used to overcome these barriers. At present, although there are still many unanswered questions regarding CAR-T cell therapy, there is no doubt that it has the potential to become an important treatment option for urological malignancies.

Keywords: CAR-T; Immunotherapy; Prostate cancer; T cells.

Publication types

  • Review

MeSH terms

  • Humans
  • Immunotherapy, Adoptive / methods*
  • Immunotherapy, Adoptive / trends
  • Male
  • Prostatic Neoplasms / immunology
  • Prostatic Neoplasms / therapy*
  • Receptors, Chimeric Antigen / genetics
  • Receptors, Chimeric Antigen / immunology*
  • Receptors, Chimeric Antigen / metabolism
  • Review Literature as Topic
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism
  • T-Lymphocytes / transplantation*
  • Tumor Microenvironment / immunology

Substances

  • Receptors, Chimeric Antigen